Review of meningioma histopathology.
The histological appearance of a meningioma is an important predictor of tumor behavior and is frequently a factor in decisions concerning therapy. The relationship between histological features and prognosis is formalized in grading schemes such as those published by the World Health Organization (WHO), most recently in 2007. Although the latest edition is an improvement over previous grading schemes, the WHO scheme still fails to fully address a variety of important issues regarding the relationship between meningioma histological characteristics and behavior. In particular, routine histological examination fails to identify the subset of Grade I tumors that behave aggressively. Because of this, many additional prognostic markers that require immunohistochemical, cytogenetic, or molecular techniques to evaluate are under investigation. Only one, immunohistochemistry for the proliferation marker, Ki 67 (MIB-1), is used routinely and it has only limited utility. It is hoped that an understanding of the genetic changes that underlie tumor progression will improve healthcare professionals' ability to predict the behavior of meningiomas.
Commins
Deborah L
DL
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA. commins@usc.edu
Atkinson
Roscoe D
RD
Burnett
Margaret E
ME
D000708:Anaplasia / Q000473:pathology; D000974:Antibodies, Antinuclear / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism; D006801:Humans; D008577:Meningeal Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008579:Meningioma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009361:Neoplasm Invasiveness
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; C440408:MIB-1 antibody